Contact
searchSearch
HMP Global
Quiz

Muscarinic Receptor-Based Options for Treatment-Resistant Schizophrenia

Craig Chepke, MD, DFAPA
09/12/2025

Related Content

a rubber stamp says "FDA Approved"
FDA Alerts
FDA Approves Monthly Olanzapine LAI for Adults With Schizophrenia
10/09/2026
Brionna Mendoza
Teva Pharmaceuticals announced the FDA approval of subcutaneous olanzapine (Weltruza) for extended-release injectable suspension on October 9, 2026.
Teva Pharmaceuticals announced the FDA approval of subcutaneous olanzapine (Weltruza) for extended-release injectable suspension on October 9, 2026.
Teva Pharmaceuticals announced...
10/09/2026
Psych Congress Network
US FDA building
FDA Alerts
FDA Authorizes First Digital Therapeutic for Negative Symptoms of Schizophrenia
10/08/2026
Maria Mantas
The US Food and Drug Administration (FDA) granted 510(k) clearance for Motivista, the first treatment specifically authorized for negative symptoms of schizophrenia in adults.
The US Food and Drug Administration (FDA) granted 510(k) clearance for Motivista, the first treatment specifically authorized for negative symptoms of schizophrenia in adults.
The US Food and Drug...
10/08/2026
Psych Congress Network
an illustration of a man sitting on the ground holding his head with his profile and brain in the background
Research Summary
Only 19.1% of First-Episode Psychosis Patients Adhere to Antipsychotics
10/06/2026
Brionna Mendoza
Young people beginning antipsychotic treatment after first-episode psychosis had low medication adherence, according to a retrospective US cohort study published in JAMA Network Open.
Young people beginning antipsychotic treatment after first-episode psychosis had low medication adherence, according to a retrospective US cohort study published in JAMA Network Open.
Young people beginning...
10/06/2026
Psych Congress Network
pills spilling out of a tipped over pill bottle
News
US Veterans Study Links SGLT2 Inhibitors to Lower Dementia Risk in Older Adults With Psychiatric Disorders
07/01/2026
Maria Mantas
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders. 
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders. 
Sodium-glucose cotransporter 2...
07/01/2026
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Desiree Matthews, PHMNP-BC; Amber Hoberg, MSN, APRN, PMHNP-BC
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use